Evotec (EVO)
(Delayed Data from NSDQ)
$3.43 USD
+0.07 (2.08%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $3.41 -0.02 (-0.58%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
EVO 3.43 +0.07(2.08%)
Will EVO be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for EVO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EVO
Evotec (EVO) Rises 12% on $75M Milestone Payment From BMY
EVO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for EVO
Evotec and Novo Nordisk Enter into Technology Development Partnership to Support Next-Generation Cell Therapies
Evotec, Novo Nordisk form technology development partnership for stem cell-based therapies
Evotec, Novo Nordisk forms technology development partnership for stem cell-based therapies
Evotec and Novo Nordisk sign partnership to support cell therapies
Evotec and X-Chem Collaborate to Accelerate Early-Stage Drug Discovery